{"schema_version":"1","generated_at":"2026-11-09T06:36:10.595Z","data_as_of":null,"url":"https://www.findmykol.com/kol/donald-colbourn","json_url":"https://www.findmykol.com/kol/donald-colbourn/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"donald-colbourn","name":"Donald Colbourn","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Memorial Sloan Kettering Cancer Center","institution_url":"https://www.findmykol.com/institution/memorial-sloan-kettering-cancer-center","city":"New York","state":"NY","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1184684235","openalex":"A5026280920"},"summary":"Donald Colbourn is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 25 publications with 210 citations (h-index 7).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":25,"cited_by_count":210,"h_index":7,"latest_activity_year":2022,"source":"works"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"Incyte Corporation","program_year":2022,"amount_usd":99.52,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1184684235"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1184684235","source":"payments"},"publications":{"total":25,"shown":5,"withheld":20,"matched_by":"OpenAlex author record","recent":[{"title":"High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma","year":2019,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2019-127575","status":"verified"},{"title":"Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","year":2019,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2019-122760","status":"verified"},{"title":"Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use","year":2017,"journal":"Leukemia & lymphoma/Leukemia and lymphoma","source_url":"https://doi.org/10.1080/10428194.2017.1306642","status":"verified"},{"title":"High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy","year":2016,"journal":"Journal of Hematology & Oncology","source_url":"https://doi.org/10.1186/s13045-016-0363-1","status":"verified"},{"title":"Rate of complete metabolic responses to immune checkpoint inhibitors in extremely heavily pre-treated patients with classical Hodgkin’s lymphoma and immunoepigenetic priming.","year":2016,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.e19012","status":"verified"}],"source":"works"},"similar":[{"name":"Howard Scher","slug":"howard-scher","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/howard-scher","json_url":"https://www.findmykol.com/kol/howard-scher/profile.json"},{"name":"Robert Motzer","slug":"robert-motzer","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/robert-motzer","json_url":"https://www.findmykol.com/kol/robert-motzer/profile.json"},{"name":"Charles Sawyers","slug":"charles-sawyers","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/charles-sawyers","json_url":"https://www.findmykol.com/kol/charles-sawyers/profile.json"},{"name":"Mark Kris","slug":"mark-kris","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/mark-kris","json_url":"https://www.findmykol.com/kol/mark-kris/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":20}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}